Merck (MSD) is no longer in talks to buy Revolution Medicines after negotiations stalled over valuation. WSJ sources say they couldn't agree on a price, though Merck was reportedly targeting the $28bn-$32bn range. Revolution's stock had climbed recently on deal rumors and their Phase III cancer drug data. AbbVie has also confirmed they aren't looking to acquire. Talks could technically restart later, but the deal is off for now.